Stéphane Bancel, Moderna CEO (Tom Williams/CQ Roll Call via AP Images)
August 3, 2023 07:26 AM EDTUpdated 12:38 PM
Pharma

Up­dat­ed: Mod­er­na ramps up R&D spend in RSV, flu and cy­tomegalovirus in Q2

Zachary Brennan

Senior Editor

When com­pared to the same quar­ter last year, R&D ex­pens­es at the mR­NA pow­er­house Mod­er­na rose by 62% to $1.1 bil­lion in this lat­est quar­ter …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

First meet­ing of CDC vac­cine ad­vi­sors in the Kennedy era is post­poned

Bridge­Bio’s heart dis­ease drug At­tru­by sails past pre­scrip­tion es­ti­mates

In sin­gle case, spinal mus­cu­lar at­ro­phy drug giv­en be­fore birth spared ba­by of ge­net­ic dis­ease symp­toms

How Keymed steered the Chi­na-to-US New­Co mod­el in biotech

Can amylin drugs take over from GLP-1s in obe­si­ty? Part­ner­less Zealand thinks so

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times